

an international reproductive health journal

Contraception

Volume 120, April 2023

Publication information: *Contraception* (ISSN 0010-7824) is published monthly by Elsevier Inc., 230 Park Avenue, New York, NY 10169. Periodicals postage paid at New York, NY, and additional mailing offices.

USA Postmaster: Send address changes to *Contraception*, Elsevier Customer Service Department, 3251 Riverport Lane, Maryland Heights, MO 63043, USA.

Annual subscription rates: United States and possessions: individual, \$503; institution, \$1,782. All other countries: individual, \$585; institution, \$1,875.

Orders, claims, and journal inquiries: Please visit our Support Hub page <https://service.elsevier.com> for assistance.

Advertising information: Advertising orders and inquiries can be sent to: USA, Canada and South America: Le-Andrea Sylvester, Elsevier Inc., 230 Park Avenue, New York, NY 10169. Tel.: (212) 633-3649, e-mail: le.sylvester@elsevier.com.

Reprints: To order 100 or more reprints for educational, commercial, or promotional use, contact the Commercial Reprints Department, Elsevier Inc., 230 Park Avenue, New York, NY 10169. E-mail: reprints@elsevier.com.

Author information: For full and complete Author Information, please go to: <http://www.contraceptionjournal.org/authorinfo>.

Author inquiries: You can track your submitted article at <http://www.elsevier.com/track-submission>. You can track your accepted article at <http://www.elsevier.com/trackarticle>. You are also welcome to contact Customer Support via <http://service.elsevier.com>.

Funding body agreements and policies: Elsevier has established agreements and developed policies to allow authors whose articles appear in journals published by Elsevier, to comply with potential manuscript archiving requirements as specified as conditions of their grant awards. To learn more about existing agreements and policies please visit <http://www.elsevier.com/fundingbodies>.

© 2023 by Elsevier Inc. All rights reserved.

This journal and the individual contributions contained in it are protected under copyright, and the following terms and conditions apply to their use in addition to the terms of any Creative Commons or other user license that has been applied by the publisher to an individual article:

Photocopying: Single photocopies of single articles may be made for personal use as allowed by national copyright laws. Permission is not required for photocopying of articles published under the CC BY license nor for photocopying for non-commercial purposes in accordance with any other user license applied by the publisher. Permission of the Publisher and payment of a fee is required for all other photocopying, including multiple or systematic copying, copying for advertising or promotional purposes, resale, and all forms of document delivery. Special rates are available for educational institutions that wish to make photocopies for nonprofit educational classroom use.

Derivative Works: Users may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions or companies. Other than for articles published under the CC BY license, permission of the publisher is required for resale or distribution outside the subscribing institution or company. For any subscribed articles or articles published under a CC BY-NC-ND license, permission of the publisher is required for all other derivative works, including compilations and translations.

Storage or Usage: Except as outlined above or as set out in the relevant user license, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the publisher.

Permissions: For information on how to seek permission visit www.elsevier.com/permissions.

Author rights: Author(s) may have additional rights in their articles as set out in their agreement with the publisher (more information at <http://www.elsevier.com/authorsrights>).

Notice: Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds or experiments described herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. To the fullest extent of the law, no responsibility is assumed by the publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein.

Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.

©TM This paper meets the requirements of ANSI Standard Z39.48-1992 (Permanence of Paper).

Original Research

- 109954** Extended use of levonorgestrel-releasing intrauterine system (LNG-IUS) 52 mg: A population pharmacokinetic approach to estimate *in vivo* levonorgestrel release rates and systemic exposure including comparison with two other LNG-IUSs
J.T. Jensen, I. Reinecke, T.M. Post, E. Lukkari-Lax, B.M. Hofmann
- 109953** Real-world effect of a potential drug-drug interaction between topiramate and oral contraceptives on unintended pregnancy outcomes
A. Sarayani, A. Winterstein, R. Cristofolletti, V. Vozmediano, S. Schmidt, J. Brown
- 109924** Single dose letrozole and misoprostol for termination of pregnancy through 63 days' gestation: A pilot study
T. Shochet, D. Turok, L.J. Frye, C.D. Sexsmith, L.M. Gawron, J.E. Kaiser, B. Winikoff
- 109920** Pregnancy and pregnancy outcomes in a prospective cohort study: Final results from the Nexplanon Observational Risk Assessment Study (NORA)
S. Reed, T.D. Minh, J.A. Lange, C. Koro, K. Heinemann
- 109914** Clinical interventions are more accurate than quantitative measurements for defining hemorrhage with dilation and evacuation
C.M. Gilbert, M.C. Matulich, M.D. Ponzini, M.D. Wilson, M.D. Creinin
- 109903** An eLearning series for staff working in Title X-funded settings: An effort to disseminate national family planning recommendations
K. Quimby, N. Spitzer, K.F. Doré, J. Kawatu
- 109957** Reproductive health services: A missed opportunity in VA primary care?
D.A. Quinn, F.E. Sileanu, S. Borrero, L.S. Callegari
- 109956** Exploring the emotional costs of abortion travel in the United States due to legal restriction
K. Kimport, M.P. Rasidjan
- 109955** At-home urine pregnancy test assessment after mifepristone and misoprostol for undesired pregnancy of unknown location
A.L. Gilbert, D. Gelfand, J. Fortin, D. Roncari, A.B. Goldberg
- 109950** Challenges accessing contraceptive care and interest in over-the-counter oral contraceptive pill use among Black, Indigenous, and people of color: An online cross-sectional survey
K. Key, A. Wollum, C. Asetoyer, M. Cervantes, A. Lindsey, R.Z. Rivera, J.R. Flint, C. Zuniga, J. Sanchez, S.E. Baum
- 109923** Self-managed medication abortion in South Korea: A retrospective records review of the uptake of medication abortion through online telemedicine prior to decriminalization
H. Atay, S. Kim, J. Kim, R. Gomperts

Contraception is indexed in *Bibliography of Reproduction, Biological Abstracts, Chemical Abstracts, Elsevier BIOBASE/Current Awareness in Biological Sciences, Current Contents, EMBASE/Excerpta Medica, Index Medicus, International Pharmaceutical Abstracts, Derwent Drug File, and Population Index*. Articles are abstracted monthly in *Core Journals in Obstetrics and Gynecology*

- 109922** “They were there because they were pregnant. Which is a really apolitical thing”—Medical student discussions of politics in abortion care in the United States
K. Rivlin, A. Kissling, M.G. Sackeim
- 109919** Experiences with small and large numbers of protesters at abortion clinics in North Carolina
W. Arey
- 109949** Exploratory study of race- or ethnicity-based discrimination among patients receiving procedural abortion care
G.A. Aguilar, L.S. Lundsberg, N.L. Stanwood, A.M. Garipey
- 109788** A randomized double blinded clinical trial to explore the clinical outcomes of vaginal isonicotinic acid hydrazide (INH) administration six hours prior to T380A intrauterine device insertion in persons delivered only by cesarean delivery
N.W. Shady, H.A. Farouk, H.F. Sallam
- 109973** A randomized double blinded clinical trial to explore the clinical outcomes of vaginal isonicotinic acid hydrazide (INH) administration six hours prior to T380A intrauterine device insertion in persons delivered only by cesarean delivery. *Contraception*. 2022 Feb 18:9788. doi: 10.1016/j.contraception.2022.01.019. Epub ahead of print.
N.W. Shady, H.A. Farouk, H.F. Sallam